T2 Biosystems (NASDAQ:TTOO) Price Target Lowered to $3.00 at Canaccord Genuity Group

T2 Biosystems (NASDAQ:TTOO) had its price target trimmed by Canaccord Genuity Group from $12.00 to $3.00 in a research note released on Monday morning, Benzinga reports. The firm currently has a hold rating on the medical equipment provider’s stock.

T2 Biosystems Trading Down 10.3 %

Shares of NASDAQ:TTOO opened at $3.01 on Monday. T2 Biosystems has a 52-week low of $2.60 and a 52-week high of $70.00. The company has a fifty day moving average of $3.66 and a 200-day moving average of $4.46.

Institutional Trading of T2 Biosystems

An institutional investor recently bought a new position in T2 Biosystems stock. Patriot Financial Group Insurance Agency LLC purchased a new position in shares of T2 Biosystems, Inc. (NASDAQ:TTOO) in the third quarter, according to its most recent filing with the SEC. The firm purchased 127,234 shares of the medical equipment provider’s stock, valued at approximately $28,000. Patriot Financial Group Insurance Agency LLC owned 3.81% of T2 Biosystems at the end of the most recent quarter. 23.18% of the stock is owned by institutional investors and hedge funds.

T2 Biosystems Company Profile

T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.